FibroGen Inc. plans to offer and sell up to $300 million of its common stock in an underwritten follow-on offering.

The company expects to grant the underwriters an option to buy additional common shares.

Net proceeds will be used to fund the expansion of product development, manufacturing and commercialization activities as well as for general corporate purposes.

Goldman Sachs & Co. LLC, Citigroup and Leerink Partners LLC are acting as joint book-running managers for the offering.